Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2006

View Archived Issues

Glenmark presents new CB2 agonists as promising antihyperalgesic candidates

Silenor effective at inducing and maintaining sleep in transient insomnia patients

Phase I results warrant abagovomab's further evaluation

GPCR inhibitor blocks cancer growth, induces apoptosis and synergizes with anticancer drugs

Sazetidine-A: a new desensitizing nicotinic ligand

Recent patents report new treatment strategies for respiratory disorders

Therapeutic agents for arteriosclerosis, hypertension, etc. disclosed in recent patents

Recent patent literature discloses novel analgesic agents

Orexo receives license payment from Endo for Rapinyl

Acadia to support new substance abuse startup company Abbey

Enrollment over half complete in phase IIb trial of CF-101 in rheumatoid arthritis

Phase II study of HCV-796 begins dosing

Preliminary three-month findings from endometriosis study of Proellex

MVA-BN polytope vaccine begins new trials in Europe

New trial studies HuMax-EGFr with chemoradiation for head and neck cancer

Dharma's iontophoretic drug delivery system shows promise in phase I study

EvoGenix completes first project under GSK collaboration

ASF-1057 begins phase IIb studies for seborrheic dermatitis

Alantos and Servier collaborate on DPP-IV inhibitor ALS-2-0426

Amgen completes acquisition of Avidia

Termination of Takeda and BioNumerik's Tavocept agreement

Renovo: pipeline update

Aridol approved in Sweden

FDA approves Tyzeka for chronic hepatitis B

Promising preliminary results for ASF-1096 formulation in cutaneous lupus erythematosus

New clinical study of levetiracetam for Tourette syndrome

Memory Pharmaceuticals discloses MEM-3454 preclinical data at the SfN meeting

The glycine transporter-1 inhibitor SSR-103800 shows promise in animal models of schizophrenia

Targeting Fc receptors: a promising approach for the treatment of B-cell malignancies

Mahonia aquifolium alkaloids may be useful against Malassezia skin infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...